Penn-led Team Presents Results From Clinical Trial of Personalized Cellular Therapy in Brain Tumor Patients
Investigational “hunter” T cells expand in blood and traffic to glioblastoma tumors
This study was created from an interdisciplinary collaboration of neurosurgeons, neuro-oncologists, neuropathologists, immunologists and transfusion medical experts. Each played a key role in its development. They engineered immune cells to seek out and attack glioblastomas (GBM) in patients. During their study, they found that these engineered immune cells were found to have acceptable safety profiles and were able to successfully migrate and infiltrate tumors. “One of the main questions in the field of T cell therapies is: can we make this work in solid tumors?” Maus said. “The barriers to CAR T cells in solid tumors are identifying targets with acceptable safety profiles, proving that T cells can get out of the blood, and that they can successfully target the tumor cells expressing the antigen without being turned off by the tumor environment.” Click here to read more.
GOODMAN Oral Board Preparation Course Tumor
Nov. 1-3, 2017; Glendale, Ariz.
2017 Managing Coding and Reimbursement Challenges
Sept. 21-23, 2017; San Antonio
Intraoperative Neurophysiology in Neurosurgery: The Essentials. 2nd Edition
Dec. 14-16, 2017; Verona, Italy
2017 Minnesota Neurosurgical Society Annual Meeting
Sept. 29-30, 2017; Rochester, Minn.
17th European Congress of Neurosurgery
Oct. 1-5, 2017; Venice, Italy